Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a First-in-Human Study of Antimalarial SJ733
NCT02661373Phase 1Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Mar 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SJ-733 in malaria (3 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Dose Limiting Toxicity at 7 days, Maximum Tolerated Dose at 7 days and 1 more. Started Mar 2016; status: completed.
02
Drugs
SJ-733
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02661373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661373.